Bremelanotide (Vyleesi) Guide
FDA-Approved HSDD Treatment
Bremelanotide is an FDA-approved melanocortin receptor agonist for acquired generalized hypoactive sexual desire disorder in premenopausal women. It is not indicated to enhance sexual performance or to treat men.
Prescription Melanocortin Therapy
Bremelanotide (Vyleesi) is a melanocortin receptor agonist indicated for acquired generalized hypoactive sexual desire disorder in premenopausal women. The FDA label does not support use for men or for sexual performance enhancement.
Track the exact dose, timing, and any adverse effects if you are following a prescribed plan, since nausea, flushing, headache, and injection-site reactions are the most common tolerability issues.
What Is Bremelanotide (PT-141)?
Bremelanotide is a prescription medication with a specific FDA indication: acquired generalized hypoactive sexual desire disorder in premenopausal women. It is not indicated to enhance sexual performance and should not be described as a general aphrodisiac.
Because it can raise blood pressure transiently and commonly causes nausea, the label recommends careful attention to cardiovascular risk, dose timing, and tolerability.
Administration Highlights
Dosing Protocol
The labeled dose is 1.75 mg subcutaneously as needed at least 45 minutes before anticipated sexual activity.
Do not exceed one dose within 24 hours or eight doses in a month.
The label advises against use in men and in postmenopausal women.
Side Effects & Safety
Key Questions
Guide FAQs
Bremelanotide is a prescription melanocortin receptor agonist approved for acquired generalized hypoactive sexual desire disorder in premenopausal women.
Yes. Shotlee supports tracking Bremelanotide doses, side effects, and health metrics. It is free to use.
Track Your Bremelanotide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.